Moving forward with Metronomic Chemotherapy: Meting report of the 2nd International workshop on Metronomic and Anti-Angiodenic chemotherapy in Pediatric Oncology.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F11%3A%230001227" target="_blank" >RIV/65269705:_____/11:#0001227 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1593/tlo.11124" target="_blank" >http://dx.doi.org/10.1593/tlo.11124</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1593/tlo.11124" target="_blank" >10.1593/tlo.11124</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Moving forward with Metronomic Chemotherapy: Meting report of the 2nd International workshop on Metronomic and Anti-Angiodenic chemotherapy in Pediatric Oncology.

Popis výsledku v původním jazyce

Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targetingtumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic chemotherapy is now considered to represent a form of multitargeted therapy. Despite representing a genuine alternative for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marsei

Název v anglickém jazyce

Moving forward with Metronomic Chemotherapy: Meting report of the 2nd International workshop on Metronomic and Anti-Angiodenic chemotherapy in Pediatric Oncology.

Popis výsledku anglicky

Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targetingtumor angiogenesis, additional mechanisms have been recently unveiled, and metronomic chemotherapy is now considered to represent a form of multitargeted therapy. Despite representing a genuine alternative for advanced and/or high-risk cancer therapy, the development of metronomic approaches in pediatric oncology still in the early stage. The few numbers of large-scale state-of-the-art clinical trials, issues regarding terminology and the limited understanding of the complex and intertwined mechanisms of action of metronomic treatments have limited progress in this important field of research. On March 18 and 19, 2010, the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology was held in Marsei

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Translational Oncology

ISSN

1936-5233

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

9

Strana od-do

189-197

Kód UT WoS článku

000294253200001

EID výsledku v databázi Scopus

—